ADU 214

Drug Profile

ADU 214

Alternative Names: ADU-214; JNJ-64041757

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Janssen
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer
  • Preclinical Ovarian cancer

Most Recent Events

  • 29 Dec 2016 Janssen reinitiates enrolment in a phase I trial in Non-small cell lung cancer in USA (IV) (NCT02592967)
  • 17 Nov 2016 Janssen suspends enrolment in a phase I trial in Non-small cell lung cancer in USA (IV) (NCT02592967)
  • 26 Jul 2016 Bristol-Myers Squibb and Janssen Biotech plan a phase II trial (Combination therapy) in Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top